Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: A randomized placebo-controlled study

American Journal of Clinical Nutrition

Volumn 77, Issue 3, 2003, Pages 658-662

  Venn, Bernard J ^a   Green, Timothy J ^a   Moser, Rudolf ^b   Mann, Jim I ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Eprova AG   (Switzerland)

Author keywords

Cardiovascular disease; Clinical trial; Folic acid; Homocysteine; L 5 Methyltetrahydrofolate; L MTHF; Plasma folate; Red blood cell folate

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; HOMOCYSTEINE; METAFOLIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MALE; NEURAL TUBE DEFECT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

EID: 0037371082     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/77.3.658     Document Type: Article

References (29)

1. Cornel MC, Erickson JD. Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly (SBA). Teratology 1997;55:134-7.
2. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996;61: 8781-97.
3. Health Canada. Food and drug regulations, Amendment Schedule no. 1066. Ottawa: Health Canada, 1997.
4. Committee on Medical Aspects of Food and Nutrition. Folic acid and the prevention of disease. Report on health and social subjects. No. 50. London: The Stationary Office, 2000.
5. National Health and Medical Research Council. Report of the Expert Panel on Folate Fortification. Sydney: Australian Government Publishing Service, 1995.
6. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:2981-6.
7. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999:131:363-75.
8. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6.
9. Schnyder G. Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-600.
10. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
11. Scott JM, Weir DG. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic acid-induced exacerbation of subacute combined degeneration in pernicious anaemia. Lancet 1981;2:337-40.
12. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull 1999;55:669-82.
13. Eprova AG. Metafolin: about the product. 2000. Internet:http://www.metafolin.com. Accessed May 2002.
14. Groen V, Moser R. Synthesis of optically pure diastereoisomers of reduced folates. Pteridines 1999;10:95-100.
15. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 1992;45:344-7.
16. Venn BJ, Mann J, Williams SM, et al. Maximum benefit of additional folic acid on homocysteine reduction may accrue from low-dose fortification. Eur J Clin Nutr 2002;56:748-54.
17. New Zealand Institute of Crop and Food Research. Food Files. The New Zealand Food Composition Database. Palmerston North, New Zealand: New Zealand Institute of Crop and Food Research, 1993.
18. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001;323: 1123-4.
19. Fohr IP, Prinz-Langenohl R, Brönstrup A, et al. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75: 275-82.
20. Boushey CJ. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
21. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000;160:422-34.
22. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-41.
23. Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-8.
24. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695-700.
25. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
26. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
27. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999;341: 1485-90.
28. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 1995;274: 1698-702.
29. Zakrzewski SF. Evidence for a single enzyme reducing folate and dihydrofolate. J Biol Chem 1960;235:2984-8.